A3P

Log in

Sanofi invests 170 million euros to expand a production site in Normandy

The pharmaceutical giant Sanofi will invest 170 million euros to expand its site in Val-de-Reuil (Eure), specializing in the production of vaccines, especially against the flu, he announced Thursday.

The new building, which the company hopes will be completed by 2021 and the launch of production in 2022, will be devoted to the production of Vaxigrip Tetra, Sanofi's newest influenza vaccine, currently distributed in 20 countries.

"As a global leader in influenza vaccines, this expansion strengthens Sanofi Pasteur's ability to address this underestimated public health problem," said David Loew, executive vice president of Sanofi and responsible for Sanofi Pasteur, the entity in charge of vaccines.

According to the WHO, seasonal influenza epidemics cause, worldwide, "about 3 to 5 million cases of serious diseases, and 250 000 to 500 000 deaths"per year.

Located 100 kilometers north-west of Paris, the Val-de-Reuil site, created in 1973, is a world leader in the production of vaccines against this virus.

In total, 200 million doses are produced each year by Sanofi in its four factories, in France, the United States, Mexico and China.

At the end of August, the company announced the acquisition of American Protein Sciences, also specialized in influenza vaccines, in order to strengthen its presence in the United States.

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P